Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts
暂无分享,去创建一个
D. Adams | T. Schumacher | L. Wessels | O. Krijgsman | D. Peeper | C. Blank | D. Vis | E. Voest | J. Haanen | F. Weeber | K. Kemper | Ji-Ying Song | P. Cornelissen-Steijger | T. Kuilman | A. Shahrabi
[1] Jos Jonkers,et al. CopywriteR: DNA copy number detection from off-target sequence data , 2015, Genome Biology.
[2] J. Larkin,et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. , 2015, Cancer cell.
[3] Ton N Schumacher,et al. Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition. , 2014, Cell reports.
[4] P. Ascierto,et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.
[5] J. Utikal,et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.
[6] Richard F. Kefford,et al. Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients , 2014, Clinical Cancer Research.
[7] R. Bernards,et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.
[8] Antoni Ribas,et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.
[9] A. McKenna,et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.
[10] Dennis C. Friedrich,et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. , 2014, Cancer discovery.
[11] Antoni Ribas,et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. , 2014, Cancer discovery.
[12] Iwei Yeh,et al. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy , 2013, Pigment cell & melanoma research.
[13] Wei Xu,et al. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. , 2013, Cell reports.
[14] K. Flaherty,et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] W. Sellers,et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, Nature.
[16] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[17] Johannes G. Reiter,et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.
[18] H. Horlings,et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. , 2012, Genes & development.
[19] Qiongqing Wang,et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. , 2012, Cancer research.
[20] Sung-Liang Yu,et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] S. Nelson,et al. Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.
[22] C. V. Jongeneel,et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma , 2011, Nature Genetics.
[23] K. Brown,et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma , 2011, Nature.
[24] Tom Misteli,et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.
[25] S. Puig,et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma , 2011, Nature.
[26] Nikhil Wagle,et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[28] M. DePristo,et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.
[29] David T. W. Jones,et al. Oncogenic FAM131B–BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma , 2011, Acta Neuropathologica.
[30] Francesca Zappacosta,et al. GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition , 2011, Clinical Cancer Research.
[31] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[32] Damien Kee,et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.
[33] M. Gerlinger,et al. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine , 2010, British Journal of Cancer.
[34] H. Hakonarson,et al. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.
[35] Richard Durbin,et al. Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..
[36] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[37] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[38] Paul Reichert,et al. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. , 2009, Biochemistry.
[39] Mehmet Toner,et al. Detection of mutations in EGFR in circulating lung-cancer cells. , 2008, The New England journal of medicine.
[40] Nobuyoshi Shimizu,et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. , 2006, Cancer research.
[41] M. Nikiforova,et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. , 2005, The Journal of clinical investigation.
[42] M. Wigler,et al. Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.
[43] J. Kuriyan,et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.